192 related articles for article (PubMed ID: 33253611)
1. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Charles P; Guillevin L
Ann Intern Med; 2020 Dec; 173(11):948. PubMed ID: 33253611
[No Abstract] [Full Text] [Related]
2. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Jain S; Chattopadhyay A; Sharma A
Ann Intern Med; 2020 Dec; 173(11):947. PubMed ID: 33253614
[No Abstract] [Full Text] [Related]
3. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Garvey TD; Warrington KJ; Koster MJ
Ann Intern Med; 2020 Dec; 173(11):947-948. PubMed ID: 33253612
[No Abstract] [Full Text] [Related]
4. The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Cartin-Ceba R; Indrakanti D; Specks U; Stone JH; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Spiera RF; Monach PA; St Clair EW; Seo P; Tchao NK; Ytterberg SR; Brunetta PG; Song H; Birmingham D; Rovin BH;
Arthritis Rheumatol; 2017 Jan; 69(1):169-175. PubMed ID: 27482943
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
6. Summary for Patients: Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Ann Intern Med; 2020 Aug; 173(3):I18. PubMed ID: 32479170
[No Abstract] [Full Text] [Related]
7. Rituximab versus cyclophosphamide for remission induction in active, severe antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Chung et al.
Jain S; Naidu GSRSNK; Sharma A
Arthritis Rheumatol; 2022 Mar; 74(3):544-545. PubMed ID: 34694068
[No Abstract] [Full Text] [Related]
8. Response to: 'Correspondence on 'Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis'' by Parikh
Smith RM; Merkel PA; Jayne D
Ann Rheum Dis; 2023 Jan; 82(1):e24. PubMed ID: 33542105
[No Abstract] [Full Text] [Related]
9. Treatment of Recurrent Antineutrophil Cytoplasmic Antibody-Associated Vasculitis After Kidney Transplant With Rituximab: A Successful Case Report.
Silva RM; Leal R; Marques MG; Rodrigues L; Santos L; Romaozinho C; Alves R; Figueiredo A
Exp Clin Transplant; 2023 Feb; 21(2):171-174. PubMed ID: 36919725
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
11. Ectopic Relapse of Anti-neutrophil Cytoplasmic Antibody-associated Pituitary Vasculitis with No Elevation of Anti-neutrophil Cytoplasmic Antibodies after Renal Remission.
Muto R; Inagaki K; Sato N; Sameshima T; Nagakura Y; Baba S; Kato N; Maruyama S; Akahori T
Intern Med; 2020 Dec; 59(24):3187-3193. PubMed ID: 32788533
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab.
Bruchfeld A; Kronbichler A; Alberici F; Fervenza FC; Jayne DRW; Segelmark M; Tesar V; Szpirt WM
Nephrol Dial Transplant; 2021 Aug; 36(9):1758-1760. PubMed ID: 33944946
[No Abstract] [Full Text] [Related]
14. Unsolved questions and concerns about treatment of anti-neutrophil cytoplasm antibody-associated vasculitides.
Chaigne B; Guillevin L
Clin Exp Rheumatol; 2016; 34(3 Suppl 97):S121-8. PubMed ID: 27087528
[TBL] [Abstract][Full Text] [Related]
15. B cells guide rituximab use in AAV remission.
Onuora S
Nat Rev Rheumatol; 2024 Feb; 20(2):67. PubMed ID: 38212541
[No Abstract] [Full Text] [Related]
16. [Should patients with ANCA-associated vasculitis undergoing maintenance therapy with rituximab receive cotrimoxazole prophylaxis?].
Mahrhofer H
Z Rheumatol; 2024 Mar; 83(2):122-124. PubMed ID: 38272971
[No Abstract] [Full Text] [Related]
17. Mild COVID-19 in ANCA-associated vasculitis treated with rituximab.
Suárez-Díaz S; Morán-Castaño C; Coto-Hernández R; Mozo-Avellaneda L; Suárez-Cuervo C; Caminal-Montero L
Ann Rheum Dis; 2021 Jun; 80(6):e99. PubMed ID: 32769153
[No Abstract] [Full Text] [Related]
18. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
[TBL] [Abstract][Full Text] [Related]
19. Treatment Strategies in ANCA-Associated Vasculitis.
Emejuaiwe N
Curr Rheumatol Rep; 2019 May; 21(7):33. PubMed ID: 31123922
[TBL] [Abstract][Full Text] [Related]
20. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
